We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Apellis (APLS) Up More Than 40% in Past 3 Months: Here's Why
Read MoreHide Full Article
Shares of Apellis Pharmaceuticals, Inc. (APLS - Free Report) have rallied 43.3% in the past three months against the industry’s decrease of 6.1%.
Image Source: Zacks Investment Research
The company has made steady progress with its lead drug, Empaveli (pegcetacoplan), which is approved by the FDA as a monotherapy treatment for adult patients suffering from paroxysmal nocturnal hemoglobinuria (“PNH”). A rare blood disorder, PNH is associated with abnormally low hemoglobin levels as the disease destroys red blood cells. The company has seen a strong initial uptake of Empaveli since its approval in May 2021.
Empaveli is approved for treatment-naïve patients as well as for those switching from Alexion’s [now part of AstraZeneca’s (AZN - Free Report) ] C5 inhibitor therapies for PNH, namely Soliris and Ultomiris (ravulizumab).
In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion, for $39 billion.
In December 2021, the European Commission approved Aspaveli for the treatment of adult patients with PNH who are anemic after treatment with a C5 inhibitor for at least three months. The drug is marketed under the trade name Empaveli in the United States.
Following the nod, Aspaveli became the first and only targeted C3 therapy to be approved in Europe for the treatment of PNH.
Apart from PNH, Apellis is developing pegcetacoplan with Sobi for other rare diseases.
Pegcetacoplan, as a monotherapy, is being evaluated in two phase III studies, namely, DERBY and OAKS, for treating patients with geographic atrophy or GA. In September 2021, Apellis announced mixed top-line data from the DERBY and OAKS studies. While the OAKS study met the primary endpoint, the DERBY study did not.
In November 2021, Apellis announced that it will submit a new drug application for intravitreal pegcetacoplan to treat GA in the first half of 2022. The company received a formal, written feedback from the FDA that reinforced its decision to do the same.
Pegcetacoplan is also being investigated in the phase II MERIDIAN study for treating amyotrophic lateral sclerosis or ALS. A potential label expansion of the drug for any of the above indications will boost sales and drive growth for the company.
Image: Bigstock
Apellis (APLS) Up More Than 40% in Past 3 Months: Here's Why
Shares of Apellis Pharmaceuticals, Inc. (APLS - Free Report) have rallied 43.3% in the past three months against the industry’s decrease of 6.1%.
The company has made steady progress with its lead drug, Empaveli (pegcetacoplan), which is approved by the FDA as a monotherapy treatment for adult patients suffering from paroxysmal nocturnal hemoglobinuria (“PNH”). A rare blood disorder, PNH is associated with abnormally low hemoglobin levels as the disease destroys red blood cells. The company has seen a strong initial uptake of Empaveli since its approval in May 2021.
Empaveli is approved for treatment-naïve patients as well as for those switching from Alexion’s [now part of AstraZeneca’s (AZN - Free Report) ] C5 inhibitor therapies for PNH, namely Soliris and Ultomiris (ravulizumab).
In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion, for $39 billion.
In December 2021, the European Commission approved Aspaveli for the treatment of adult patients with PNH who are anemic after treatment with a C5 inhibitor for at least three months. The drug is marketed under the trade name Empaveli in the United States.
Following the nod, Aspaveli became the first and only targeted C3 therapy to be approved in Europe for the treatment of PNH.
Apart from PNH, Apellis is developing pegcetacoplan with Sobi for other rare diseases.
Pegcetacoplan, as a monotherapy, is being evaluated in two phase III studies, namely, DERBY and OAKS, for treating patients with geographic atrophy or GA. In September 2021, Apellis announced mixed top-line data from the DERBY and OAKS studies. While the OAKS study met the primary endpoint, the DERBY study did not.
In November 2021, Apellis announced that it will submit a new drug application for intravitreal pegcetacoplan to treat GA in the first half of 2022. The company received a formal, written feedback from the FDA that reinforced its decision to do the same.
Pegcetacoplan is also being investigated in the phase II MERIDIAN study for treating amyotrophic lateral sclerosis or ALS. A potential label expansion of the drug for any of the above indications will boost sales and drive growth for the company.
Apellis Pharmaceuticals, Inc. Price
Apellis Pharmaceuticals, Inc. price | Apellis Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Apellis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector include Sarepta Therapeutics, Inc. (SRPT - Free Report) and vTv Therapeutics Inc. (VTVT - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Sarepta Therapeutics’ loss per share estimates have narrowed 28.2% for 2022, over the past 60 days.
Earnings of Sarepta Therapeutics have surpassed estimates in two of the trailing four quarters, and missed the same on the other two occasions.
vTv Therapeutics’ loss per share estimates have narrowed 21.7% for 2022, over the past 60 days.
vTv Therapeutics’ earnings have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.